Clinical Trial: A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.

U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07354022) titled 'A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.' on Jan. 08.

Brief Summary: The study is being conducted to evaluate the efficacy and safety of HRS-8080 combined with dalpiciclib versus fulvestrant combined with dalpiciclib in patients with locally advanced/metastatic breast cancer who had developed drug resistance to prior adjuvant endocrine therapy.

Study Start Date: Dec., 2026

Study Type: INTERVENTIONAL

Condition: Locally Advanced or Metastatic Breast Cancer

Intervention: DRUG: HRS-8080 Tablet ; Dalpic...